About Risek 40mg
Riske 40mg Infusion/Injection is an alternative to oral therapy for the treatment of duodenal ulcers, gastric ulcers, NSAID-associated gastric and duodenal ulcers, reflux oesophagitis, and Zollinger-Ellison syndrome. It contains omeprazole 40mg powder for Infusion.
How effective is Risek 40mg?
Risek 40mg Infusion/Injection is helpful to control, prevent, and improve the following diseases, conditions, and symptoms like duodenal ulcers, gastric ulcers, reflux oesophagitis, gastro-oesophageal reflux disease, and Zollinger-Ellison syndrome. It reduces gastric acid secretion through a unique mechanism of action. Risek 40mg is also used to decrease the risk of stomach ulcer after an endoscopy treatment.
What dose should I choose?
For Adults, Take Risek 40mg once daily. The initial dosage for patients with Zollinger-Ellison Syndrome is 60mg daily. If dosage exceeds 60mg, then it should be divided and given twice a day. Try not to exceed the given dosage. If you have any medication queries, then consult with your doctor or a pharmacist.
What are the side effects and other warnings when taking Risek 40mg?
All products with an active ingredient can cause side effects, although they are rare.
Side effects can include:
- Bloating.
- Cough.
- Darkened urine.
- Drowsiness.
- Fast heartbeat.
- Indigestion.
- Fever.
- Joint or muscle pain.
- Mood or mental changes.
- Muscle spasms.
- Nausea.
These effects tend to be temporary and may disappear when your body gets adjusted according to this medication. You should stop the use immediately and consult your doctor or a pharmacist if an allergic reaction occurs.
Symptoms of an allergy include:
- Rash
- Itching/ swelling
- Severe dizziness
- Trouble breathing.
If you are pregnant, might become pregnant, or think you may be pregnant or breast-feeding or planning to breast-feed, notify your doctor or a pharmacist before using this Infusion.
If you have any concerns about any potential side effects, please speak to the experts.
Reviews
Clear filtersThere are no reviews yet.